A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer

Nakasato, Tatsuhiko; Kusaka, Chiho; Ota, Mika; Yuki, Hitomi; Unoki, Tsutomu; Oshinomi, Kazuhiko; Murata, Jun; Maeda, Yukihide; Shichijo, Takeshi; Naoe, Michio; Ogawa, Yoshio

doi:10.3390/diagnostics10030151

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, KDM4B recruits splicing factors to splice in specific regions of chromatin, transforming the precursor RNA of AR into the precursor RNA of AR-V7. The AR-V7 protein is a type of androgen receptor variants that can function as an AR without the influence of ADT ( Nakasato et al, 2020 ). After knockout of KDM4B, the rapid decrease in AR-V7 content inhibits the growth of prostate cancer cells and enhances the efficacy of enzalutamide ( Duan et al, 2019b ).…”

Section: The Roles Of Kdm4b In Various Kinds Of Cancersmentioning

confidence: 99%

The Diverse Roles of Histone Demethylase KDM4B in Normal and Cancer Development and Progression

Wang

Cai

Zhao

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Histone methylation status is an important process associated with cell growth, survival, differentiation and gene expression in human diseases. As a member of the KDM4 family, KDM4B specifically targets H1.4K26, H3K9, H3K36, and H4K20, which affects both histone methylation and gene expression. Therefore, KDM4B is often regarded as a key intermediate protein in cellular pathways that plays an important role in growth and development as well as organ differentiation. However, KDM4B is broadly defined as an oncoprotein that plays key roles in processes related to tumorigenesis, including cell proliferation, cell survival, metastasis and so on. In this review, we discuss the diverse roles of KDM4B in contributing to cancer progression and normal developmental processes. Furthermore, we focus on recent studies highlighting the oncogenic functions of KDM4B in various kinds of cancers, which may be a novel therapeutic target for cancer treatment. We also provide a relatively complete report of the progress of research related to KDM4B inhibitors and discuss their potential as therapeutic agents for overcoming cancer.

show abstract

Section: The Roles Of Kdm4b In Various Kinds Of Cancersmentioning

confidence: 99%

The Diverse Roles of Histone Demethylase KDM4B in Normal and Cancer Development and Progression

Wang

Cai

Zhao

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…The processes involved in CTC enrichment and ARV-7 status determination under each of the three methods have been previously described. 9,17,18 The AdnaTest platform was applicable only for patients recruited in Singapore as samples needed to be processed within 4 hours of collection.…”

Section: Methodsmentioning

confidence: 99%

Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer

Ang,

Chan,

Ong

et al. 2024

JCO Precis Oncol

View full text Add to dashboard Cite

PURPOSE Androgen receptor splice variant 7 (ARV-7) is a resistance mechanism to hormonal therapy in metastatic castrate-resistant prostate cancer (mCRPC). It has been associated with poor outcomes. On progression to castrate resistance, ARV-7 positivity has been identified in global populations at an incidence of 17.8%-28.8%. Here, we characterize the incidence of ARV-7 positivity in Asian patients with mCRPC in a prospective fashion and evaluate its implications on treatment outcomes. METHODS Patients with mCRPC from multiple centers in Southeast and East Asia were enrolled in a prospective manner before initiation of androgen receptor signaling inhibitors or docetaxel. ARV-7 status was evaluated at baseline with three commercially available assays: AdnaTest Prostate Cancer platform, Clearbridge method, and IBN method. Clinical outcomes at progression were assessed. The primary end point of this study was prevalence of ARV-7 positivity; secondary end points were incidence of ARV-7 positivity, prostate specific antigen (PSA) response rate, PSA progression-free survival (PFS), and overall survival (OS). RESULTS A total of 102 patients with a median age of 72 years at enrollment participated. Overall, an incidence of ARV-7 positivity of between 14.3% and 33.7% in Asian patients with mCRPC was demonstrated depending on the assay used. Patients found to have ARV-7 positivity at enrollment had a numerically worse PSA PFS compared with ARV-7 negative patients. CONCLUSION In this study, the incidence of ARV-7 positivity in Asian patients with mCRPC was shown to be similar to the global population. Patients with ARV-7 positivity appear to have more aggressive disease with numerically worse PSA PFS and OS. Further prospective studies are needed to fully characterize the relationship that ARV-7 positivity has on prognosis of Asian patients with mCRPC.

show abstract

“…There were both consistencies and differences in the expression of PD-L1 in tumor tissue and CTCs, and parallel evaluation of peripheral and local immunity provided more comprehensive information [ 82 , 83 ]. In addition, the expression of the nuclear androgen receptor splice variant 7 (AR-V7) protein on CTCs is related to androgen receptor-targeted drug resistance, which can guide drug selection for metastatic castration-resistant prostate cancer (mCRPC) patients [ 84 , 85 ]. The expression of specific proteins on CTCs could be used to predict drug sensitivity and select appropriate drugs.…”

Section: Overview Of the Clinical Application Value Of Ctcsmentioning

confidence: 99%

Detection and clinical significance of circulating tumor cells in colorectal cancer

et al. 2021

View full text Add to dashboard Cite

Histopathological examination (biopsy) is the “gold standard” for the diagnosis of colorectal cancer (CRC). However, biopsy is an invasive method, and due to the temporal and spatial heterogeneity of the tumor, a single biopsy cannot reveal the comprehensive biological characteristics and dynamic changes of the tumor. Therefore, there is a need for new biomarkers to improve CRC diagnosis and to monitor and treat CRC patients. Numerous studies have shown that “liquid biopsy” is a promising minimally invasive method for early CRC detection. A liquid biopsy mainly samples circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNA (miRNA) and extracellular vesicles (EVs). CTCs are malignant cells that are shed from the primary tumors and/or metastases into the peripheral circulation. CTCs carry information on both primary tumors and metastases that can reflect dynamic changes in tumors in a timely manner. As a promising biomarker, CTCs can be used for early disease detection, treatment response and disease progression evaluation, disease mechanism elucidation, and therapeutic target identification for drug development. This review will discuss currently available technologies for plasma CTC isolation and detection, their utility in the management of CRC patients and future research directions.

show abstract

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer

Cited by 3 publications

References 24 publications

The Diverse Roles of Histone Demethylase KDM4B in Normal and Cancer Development and Progression

The Diverse Roles of Histone Demethylase KDM4B in Normal and Cancer Development and Progression

Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer

Detection and clinical significance of circulating tumor cells in colorectal cancer

Contact Info

Product

Resources

About